Has David Haines, MD received payments from drug or device companies?

Yes. Drug and device makers reported $492,345 in general payments to David Haines, MD across 134 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Haines, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Haines, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Haines, MD

Cardiovascular Disease · Royal Oak, MINPI 1518949718

Payments from drug & device makers

What this record shows

This record is dominated by other: $418,097 of the $492,345 with a category attached, or 84.9%. Medtronic accounts for 88.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $336,520 and has fallen 86.6% since, to $44,929 in 2024. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$492,345in general payments, 2019–2025

Across 134 payments — averaging $3674.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$434K
Boston Scientific$34K
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
Philips North America LLC$5K
Cortex, Inc.$3K
Biosense Webster, Inc.$2K
plus $5K from 6 others

$462,143in research payments, 2019–2025

Across 45 payments — averaging $10,270 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$413K
Abbott$20K
Kardium Inc.$20K
Medical Device Business Services, Inc.$9K

What the payments were for

Consulting fees$18,2844%
Speaking & faculty fees$35,5877%
Grants$6,7641%
Travel & lodging$7,7092%
Food & beverage$5,7781%
Education$140%
Gifts$1120%
Other$418,09785%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	51	$434,257
Boston Scientific	46	$34,055
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	5	$8,176
Philips North America LLC	4	$5,073
Cortex, Inc.	2	$3,172
Biosense Webster, Inc.	5	$2,272
Integer Holdings Corporation	5	$2,271
Altathera Pharmaceuticals LLC	3	$1,669
Abbott	7	$699
Ablacon, Inc.	3	$393
Acutus Medical, Inc.	2	$194
Cardiofocus, Inc.	1	$115

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$492,345 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan →

Medicare billing

Part B allowed, 2024

$8,849

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	115	$155,751
XareltoRivaroxaban	30	$38,470
Repatha SureclickEvolocumab	11	$6,892
Dofetilide	22	$2,924
Flecainide Acetate	23	$1,293
Amiodarone Hcl	35	$1,173
Metoprolol Succinate	48	$974
Atorvastatin Calcium	27	$350
SotalolSotalol Hcl	16	$226
Losartan Potassium	13	$186
Carvedilol	14	$108
Lisinopril	16	$103

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Royal Oak

Douglas HorstmanshofRoyal Oak$407K
Elvis CamiRoyal Oak$45K
Marschall RungeAnn Arbor$1.8M
Jihad MustaphaGrand Rapids$1.6M
Vallerie McLaughlinAnn Arbor$947K
Pedro Villablanca SpinettoDetroit$620K
Stanley ChetcutiAnn Arbor$573K
Steven AlmanyTroy$471K
David StroblLansing$445K
Herman KadoSouthfield$442K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →